Joe Rogan's Supplement Stack: What He Actually Takes (And What's Actually Backed)
Joe Rogan's supplement stack, component by component, evidence-graded. AG1, vitamin D, fish oil, creatine, alpha-GPC, glutamine, quercetin, elderberry, and the TRT context.
In 2007, Joe Rogan started discussing his supplement stack publicly on the podcast that would, by 2024, average 14.5 million listeners per episode. Eighteen years of conversation has cemented a roster of products in the public imagination as "what Joe takes." Vitamin D, fish oil, creatine, AG1, alpha-GPC, glutamine, quercetin, elderberry — the lineup is largely stable, occasionally expanded, and selectively endorsed. He is also an investor in AG1 and a public TRT user, which shapes how the rest of the stack should be evaluated.
The market response is significant. AG1 became the highest-grossing single greens powder largely because of Rogan's endorsement. Onnit's alpha-GPC products sold consistently for the same reason until Rogan sold the company in 2021. The reach is real. The evidence behind each component is uneven. Graded honestly, the stack splits into three categories: strongly supported, mechanistically reasonable, and weakly supported.
The Grading System
Each component below is graded against a consistent rubric:
Strong: Multiple RCTs, meta-analytic evidence, or position statements from professional bodies (ISSN, Endocrine Society). Effect size is clinically meaningful and replicable.
Moderate: Several RCTs but with heterogeneity in results, smaller effect sizes, or context-dependent benefit. Mechanism is well-established.
Preliminary: Limited or small-trial human evidence. Mechanism is plausible. Effect is unproven in well-powered trials.
Weak: No rigorous human RCT evidence at meaningful dose, or contradictory findings. Marketing claims exceed the data.
Vitamin D3 + K2 — Strong (Context-Dependent)
The vitamin D case has shifted significantly since 2018. Pre-VITAL trial (Manson 2019, NEJM, n=25,871), supplementation was assumed to broadly reduce cardiovascular events and cancer mortality. VITAL randomized adults to 2000 IU vitamin D3 daily versus placebo for a median of 5.3 years and found no significant reduction in cardiovascular events or invasive cancer at the primary endpoint.
The post-VITAL position is more measured. Vitamin D supplementation reliably raises serum 25(OH)D. The biomarker movement is real. The downstream clinical benefit is most defensible in deficient populations (25(OH)D < 20 ng/mL), in older adults at fall risk, and for bone health. Universal supplementation in healthy adults with adequate sun exposure shows smaller benefit than mid-2010s consensus assumed.
Rogan's protocol — 5000 IU vitamin D3 plus K2 (MK-7) — is defensible for most adults living above 35° latitude with limited sun exposure. K2 supplementation alongside vitamin D has theoretical justification (preventing calcium misdirection to soft tissue) and the Rotterdam Study observational data. The combined form (D3 + K2) is reasonable, well-tolerated, and inexpensive.
Grade: Strong for deficient adults, Moderate for the general population. Test serum 25(OH)D before assuming you need it; target range 30–50 ng/mL.
Fish Oil (EPA + DHA) — Strong
Omega-3 fatty acids EPA and DHA from fish oil have the largest evidence base for triglyceride reduction at higher doses (2–4g/day combined EPA+DHA). The REDUCE-IT trial (Bhatt 2019, NEJM) of icosapent ethyl (purified EPA) at 4g/day in statin-treated patients showed a 25% reduction in major adverse cardiovascular events over five years.
For general populations using mixed EPA/DHA fish oil at 1–2g/day, the data is more mixed — VITAL's omega-3 arm did not show overall cardiovascular event reduction, though subgroup analysis showed benefit in low fish consumers and African American participants. The triglyceride-lowering effect is consistent across trials.
Rogan's dosing is reportedly in the 2–3g/day combined EPA+DHA range. This is consistent with the dose-response window where triglyceride lowering and anti-inflammatory effects appear. Third-party tested products (IFOS certified, no detectable mercury or PCBs) are non-negotiable — fish oil quality varies enormously.
Grade: Strong for triglyceride management and inflammatory disease support. Moderate for general cardiovascular primary prevention. Cleanly fits in the inflammation-reduction protocol.
Creatine Monohydrate — Strong
The single deepest evidence base on the entire stack. Creatine monohydrate at 5g/day has hundreds of RCTs, an ISSN position stand (Kreider 2017), and effect sizes for strength, lean mass, and exercise performance that have been replicated across decades and populations.
Beyond performance, creatine has emerging cognitive evidence. Avgerinos's 2018 systematic review in Experimental Gerontology compiled six RCTs in healthy adults showing improvement in short-term memory and reasoning, particularly in vegetarians and older adults. Newer trials have extended this to sleep-deprivation contexts and mood symptoms in depression.
The safety profile is exceptional. Decades of supplementation in athletes show no kidney, liver, or hormonal adverse effects in healthy individuals. The "creatine causes hair loss" concern from a 2009 South African rugby player trial (Van der Merwe) measured DHT but not hair loss — and has not replicated in subsequent trials.
Grade: Strong. Creatine monohydrate at 5g/day is the single most defensible supplement decision in the stack. Skip the "loading phase" — 5g daily continuously reaches saturation in 3–4 weeks.
AG1 (Athletic Greens) — Moderate Formula, Weak Value Proposition
AG1 is a multivitamin, probiotic, and adaptogen blend marketed at a premium. The formula contains 75 ingredients — vitamins, minerals, greens powders, probiotics, mushroom extracts, and adaptogenic herbs. The total nutrient profile is reasonable: it functions as a comprehensive multivitamin with some additional bioactives.
The marketing claims (energy, immune support, gut health, recovery) outpace what a multivitamin and probiotic can deliver in adults who are not deficient. AG1 has minimal independent clinical evidence — the company has funded small studies, but none have appeared in high-impact peer-reviewed journals at the time of writing.
The honest value framing: AG1 costs $99/month at single subscription. A high-quality multivitamin ($15/month), a 50-billion CFU probiotic ($25/month), and a basic electrolyte powder ($15/month) replicate most of the functional value at less than half the cost. For adherence-challenged adults who would otherwise skip nutritional foundations entirely, AG1 wins on simplicity. For evidence-driven optimizers, single-ingredient sourcing is more efficient per dollar.
Grade: Moderate formula, weak value. Adherence-positive for the time-poor, financially inefficient for the supplement-literate.
Alpha-GPC — Preliminary
Alpha-glycerylphosphorylcholine (alpha-GPC) is a choline donor that crosses the blood-brain barrier efficiently and elevates acetylcholine. The strongest acute trial is Bellar 2015 in JISSN — 600mg taken 45 minutes pre-exercise produced a measurable increase in lower-body isometric force production in trained adults over six days.
Chronic cognitive evidence in healthy adults is limited. Most positive cognitive trials of alpha-GPC are in cognitive decline populations (mild cognitive impairment, post-stroke), where choline status is impaired. The translation to healthy-adult cognitive optimization is mechanistically plausible but not well-tested.
Practical dose: 300–600mg taken 30–45 minutes before training or focused cognitive work. Side effects are rare at this dose. Tolerance development is not well-characterized in long-term use.
Grade: Preliminary. Acute power output evidence is real; chronic cognitive optimization claim is unproven. See modafinil alternatives 2026 and the caffeine-theanine stack for cleaner cognitive evidence.
Glutamine — Weak (in Healthy Adults)
L-glutamine supplementation has strong evidence in clinical populations — burn patients, surgical recovery, critical illness — where glutamine becomes conditionally essential. In healthy adults at typical training volumes, the case is much weaker. Glutamine is abundantly present in the diet (5–10g/day from meat, dairy, and eggs in typical Western diets), and the body's plasma glutamine pool is large.
Trials of supplemental glutamine in healthy athletes (5–20g/day) show modest or null effects on recovery, immune function, and muscle protein synthesis when adequate protein intake is in place. The "gut health" claim — that glutamine repairs intestinal lining — has support in chronic GI disease populations but limited evidence in healthy adults with normal intestinal function.
Grade: Weak for healthy adults with adequate protein intake. Strong in clinical populations (burn, surgical recovery, IBD). For Rogan's training volume and protein intake, marginal.
Quercetin — Preliminary
Quercetin is a flavonoid found in onions, apples, and capers. It has anti-inflammatory activity, mast cell stabilization effects, and weak antiviral activity in vitro. The COVID-era interest in quercetin + zinc + vitamin D drove product sales beyond what the human evidence supported.
Trials of quercetin for upper respiratory infection prevention in athletes show modest reductions in infection incidence (Nieman 2010). Allergy symptom trials show modest benefit. The chronic cardiovascular benefit is theoretical from in vitro and animal models; large human outcome trials do not exist.
Practical dose: 500–1000mg/day. Bioavailability is poor; quercetin phytosome (Lecithin-bound) or co-administered with bromelain improves absorption.
Grade: Preliminary for upper respiratory protection in heavy training; weak for chronic health benefit in general populations.
Three things on Rogan's stack have the kind of evidence that should outlive trends. The rest is in the same evidence zone as most popular supplements: plausible, low-risk, and sold harder than the data deserves.
Elderberry (Sambucus nigra) — Preliminary
Elderberry has small-trial support for reducing cold and flu duration when taken acutely at symptom onset. Tiralongo's 2016 trial in Nutrients gave 312 air travelers elderberry extract or placebo around international flights — symptom duration was reduced by approximately two days in the elderberry group.
The safety profile is benign at standard doses (uncooked elderberry is toxic; commercial products use cooked or extract forms). The case for daily prophylactic use is thinner than for acute use during early symptoms.
Grade: Preliminary for acute use during early symptoms; weak for daily prophylaxis.
Components Rogan Has Cycled In and Out
Beyond the consistent core, several products have appeared and disappeared from Rogan's public stack over the years. NMN was added during the David Sinclair-era enthusiasm and remained ambiguous after FDA reclassified NMN as drug-excluded in 2022 — see the NMN vs NR comparison for the regulatory and evidence detail. Resveratrol entered alongside NMN and has similar evidence problems: meaningful animal data, weak human translation, and persistent bioavailability concerns. Both compounds have rotated through endorsements at various biohacker brands.
Onnit's Alpha Brain — the nootropic blend Rogan promoted heavily as the founder and longtime owner of Onnit before selling to Unilever in 2021 — has small placebo-controlled trials showing modest cognitive effects in healthy adults. The trial base is internally funded and modest in scope. After selling Onnit, Rogan's stack mentions of Alpha Brain decreased, which is its own data point about endorsement dynamics in the supplement space.
The pattern is consistent: high-profile inclusions tied to commercial relationships, lower-profile inclusions tied to genuine personal use, and a rotating periphery that shifts with the biohacker zeitgeist. The consistent core (creatine, vitamin D, fish oil) appears across all eras of his public discussion; the periphery moves.
The TRT Context Changes Everything
Rogan has publicly discussed testosterone replacement therapy under physician supervision since approximately 2007. This single intervention pharmacologically dominates most of the recovery, strength, and muscle-mass benefit that would otherwise be attributed to the supplement stack.
Exogenous testosterone at replacement doses (typically 100–200mg/week of testosterone cypionate or enanthate) raises serum total testosterone into the upper-normal or supraphysiologic range. The downstream effects — improved protein synthesis, faster recovery, better body composition, sustained libido and energy — are pharmacologically large. Supplement effects layered on top of this are small relative magnitude.
The implication for readers: do not assume "Joe Rogan's stack" produces "Joe Rogan's results." The TRT is the foundation. The supplements operate around it. For men without TRT, the same stack will produce a smaller composite effect — and the cortisol-muscle-recovery dynamics and total testosterone optimization fundamentals matter more proportionally.
Where Rogan Is Right, Where He's Wrong
The strongest calls in Rogan's public position:
Right on creatine. Rogan has consistently advocated creatine for cognitive and athletic benefit. The evidence backs this — creatine is the single most defensible supplement decision in his stack.
Right on vitamin D for deficient populations. Most adults in temperate latitudes are below the 30 ng/mL serum 25(OH)D threshold. Supplementation at 2000–5000 IU is reasonable population guidance.
Right on fish oil for inflammation and triglycerides. The 2–3g/day combined EPA+DHA dose targets the evidence-supported zone.
Right on TRT transparency. Rogan's public disclosure of TRT use, while controversial, set a precedent for honesty about pharmacological inputs that the broader fitness influencer space has largely declined to follow. The transparency framework — disclose what you take, do not pretend supplements alone produce the results — is itself a more important contribution than any individual product on the stack.
Overstated on AG1. The product is reasonable; the marketing exceeds the data; the price premium is hard to justify when single-ingredient sourcing replicates the formula at half the cost.
Overstated on alpha-GPC for chronic cognition. Acute pre-workout use has trial support. The "smart drug" framing for daily cognitive optimization is not well-supported in healthy adults.
Overstated on glutamine. In healthy adults with adequate protein intake, the marginal benefit is small.
Reasonable but small effect on quercetin and elderberry. Both have acute-use case data; daily prophylactic claims exceed the evidence.
Who Benefits Most From This Stack
The honest profile of the high-value subset of Rogan's stack:
Men over 40 with elevated training volume. Creatine, vitamin D + K2, and fish oil at 2g+/day are evidence-supported and inexpensive. This three-component core costs ~$25–35/month and captures most of the demonstrable benefit.
Adults skipping foundational nutrition. AG1 at $99/month buys adherence to a vitamin and probiotic floor. The cost premium is the adherence purchase, not the per-dose efficacy.
Adults with confirmed deficiency. Test serum 25(OH)D and ferritin before assuming the stack is necessary. Deficient adults benefit most; replete adults benefit least.
The poor candidates:
Men under 30 with no clinical issues and good baseline diet. The marginal benefit is small. Foundational interventions — sleep, cortisol management, training quality — have higher leverage.
Men hoping the stack will replicate TRT-driven results. It will not. Supplements operate at the margins. Exogenous testosterone is a categorical intervention. The two are not interchangeable.
Men without baseline biomarkers. The stack is more efficient when targeted to actual deficiency or dysregulation. Vitamin D for the 25(OH)D-deficient produces large effects; for the replete it produces marginal effects. Fish oil for the high-triglyceride patient is meaningful; for the well-controlled it is marginal. CoQ10 for the statin user is meaningful; for the non-statin user without measured deficiency it is marginal. Untargeted stack acquisition is the supplement industry's preferred customer state — it maximizes spend without maximizing benefit.
The Protocol
-
Lock the three Strong-Evidence anchors. Creatine monohydrate 5g/day, vitamin D3 5000 IU + K2 (MK-7) 100mcg/day, fish oil 2g/day combined EPA+DHA. This core costs ~$25–35/month and captures the majority of the defensible benefit on the stack.
-
Test before scaling. Serum 25(OH)D, hsCRP, ApoB, and total testosterone. The stack should respond to baseline biology, not to celebrity endorsement.
-
Skip AG1 unless adherence is the bottleneck. If you would otherwise skip multivitamin, probiotic, and electrolyte foundations entirely, AG1 wins on convenience. If you can self-assemble, source single ingredients — quality multivitamin ($15), 50-billion CFU probiotic ($25), electrolyte powder ($15) — for less than half the AG1 cost.
-
Add alpha-GPC only as acute pre-training. 300–600mg 30–45 minutes before training or focused cognitive work. Skip the chronic daily-cognition framing — the evidence does not support it in healthy adults.
-
Skip glutamine in healthy adults with adequate protein intake (>1.6g/kg/day). The marginal benefit is small and the cost is real.
-
Use quercetin and elderberry acutely, not chronically. At first sign of viral illness, both are reasonable additions for 5–7 days. As daily prophylaxis, the evidence is thin and the cost compounds.
-
Build the executive performance and longevity-extension layers separately. The supplement core handles foundations. Cognitive performance, longevity-specific interventions (NAD+ precursors, urolithin A — see NMN vs NR), and metabolic optimization (see how to lower ApoB naturally) deserve their own protocols, not assimilation into a celebrity stack.
-
Reassess every 6 months. Stacks drift. Add components only with biomarker justification. Subtract components that have not earned their place. The stack should shrink as evidence sharpens — not grow because something new appeared on a podcast.
Key Takeaways
- Three components on Rogan's stack have Strong evidence — creatine monohydrate, vitamin D3 + K2, and fish oil EPA/DHA.
- AG1 has a Moderate formula but a Weak value proposition; single-ingredient sourcing replicates the formula at less than half the cost.
- Alpha-GPC has Preliminary evidence — strong acute pre-workout effect, weak chronic cognitive optimization claim.
- Glutamine in healthy adults with adequate protein is Weak; the case lives in clinical populations.
- TRT is the foundation underneath Rogan's results; the same stack without TRT produces a smaller composite effect, and readers should not conflate the two.
Want to know which parts of your stack are earning their place? → Take the PrimalPrime Biological Age Calculator to baseline your biomarkers before scaling supplement spend.